2-[2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]acetamide
• 英文别名: 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]acetamide
• 化学式: C₁₅H₁₃N₃O₅
• 分子量: 315.28
• InChiKey: RIBHJZYOXCJNTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：Celgene Corporation

  公开号：US20140113935A1

  公开（公告）日：2014-04-24

  This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本发明涉及N-甲基氨甲基异吲哚啉化合物及其药学上可接受的盐、溶剂化合物、立体异构体和前药。本发明还披露了这些化合物的使用方法和制药组合物。
• METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20180134684A1

  公开（公告）日：2018-05-17

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
• TUNABLE ENDOGENOUS PROTEIN DEGRADATION
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20220135967A1

  公开（公告）日：2022-05-05

  The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.